Approval · Notice of Compliance 2048 · 1999
SEREVENT: Notice of Compliance 2048
Issued June 29, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2048
- Date
- June 29, 1999
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Bronchodilator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEREVENT | 02211742 | Cancelled Post Market |
Medicinal ingredients
- SALMETEROL XINAFOATE 25 MCG per ACT